Zika virus (ZIKV) has recently emerged as a pandemic associated with severe neuropathology in newborns and adults 1 . There are no ZIKV-specific treatments or preventatives. Therefore, the development of a safe and effective vaccine is a high priority. Messenger RNA (mRNA) has emerged as a versatile and highly effective platform to deliver vaccine antigens and therapeutic proteins 2,3 . Here we demonstrate that a single low-dose intradermal immunization with lipid-nanoparticle-encapsulated nucleosidemodified mRNA (mRNA-LNP) encoding the pre-membrane and envelope glycoproteins of a strain from the ZIKV outbreak in 2013 elicited potent and durable neutralizing antibody responses in mice and non-human primates. Immunization with 30 μg of nucleosidemodified ZIKV mRNA-LNP protected mice against ZIKV challenges at 2 weeks or 5 months after vaccination, and a single dose of 50 μg was sufficient to protect non-human primates against a challenge at 5 weeks after vaccination. These data demonstrate that nucleoside-modified mRNA-LNP elicits rapid and durable protective immunity and therefore represents a new and promising vaccine candidate for the global fight against ZIKV.
vaccines (reviewed in ref. 16 ). Vaccination with mRNA offers several advantages over other vaccine platforms: (i) it is a non-integrating, non-infectious gene vector that can be readily designed to express any protein with high efficiency; (ii) it has the potential for cost-effective and highly scalable manufacturing; and (iii) small doses are sufficient to induce protective immune responses.
Here, we designed a potent anti-ZIKV vaccine in which the premembrane and envelope (prM-E) glycoproteins of ZIKV H/PF/2013 (ref. 17) are encoded by mRNA (Extended Data Fig. 1a ) containing the modified nucleoside 1-methylpseudouridine (m1Ψ), which prevents innate immune sensing and increases mRNA translation in vivo 18 . Nucleoside-modified ZIKV prM-E mRNA was prepared for vaccination by encapsulation in lipid nanoparticles (LNPs), which have been shown to mediate efficient and prolonged protein expression by mRNA in vivo 19 . Studies of ZIKV and other flaviviruses have demonstrated that co-expression of pre-membrane and envelope proteins is sufficient to assemble and secrete subviral particles 12, 20 . ZIKV prM-Eencoding mRNA was first characterized by transfecting HEK293T cells and human and mouse dendritic cells. ZIKV envelope (E) protein was produced by all cell types and was secreted into the supernatant of HEK293T cells (Extended Data Fig. 1b ). We hypothesize that dendritic cells also secrete E protein and that it is rapidly internalized by endocytosis, as has been proposed for HIV gag 21 . E protein in the supernatant of HEK293T cells was pelleted by ultracentrifugation when incubated with PBS, but not with 0.5% Triton X-100, consistent with subviral particle production from prM-E mRNA 20 (Extended Data Fig. 1c ).
The immune response induced by the nucleoside-modified ZIKV prM-E mRNA-LNP vaccine was first analysed in C57BL/6 mice. Animals were immunized by intradermal injection of 30 μ g of ZIKV prM-E mRNA-LNP or polycytidylic acid (poly(C)) RNA-LNP as a negative control. No inflammation or other adverse events were observed at the sites of injection. Polyfunctional E-protein-specific CD4 + T cell responses were detected on the basis of intracellular IFNγ , TNF (also known as TNFα) and IL-2 production by splenocytes stimulated with ZIKV E protein at week 2 after vaccination ( Fig. 1a and Extended Data Fig. 2) . ZIKV E-protein-specific immunoglobulin G (IgG) in the serum developed quickly in vaccinated mice and stabilized at an endpoint titre of 180,000 (90 μ g ml −1 ) at weeks 8-12 ( Fig. 1b and Extended Data Fig. 3a ). Anti-ZIKV neutralizing antibodies (nAb) were measured using two independent assays: a standard LETTER RESEARCH plaque-reduction neutralization test (PRNT) and a ZIKV reporter viral particle (RVP) assay 12 . The mean PRNT 50 titre against ZIKV MR-766 peaked at around 1,300 at week 8 ( Fig. 1c ) and was relatively stable until week 12. The mean RVP nAb titre (EC 50 ) against ZIKV H/PF/2013 reached approximately 10 5 at weeks 8-12 (Fig. 1d ). The detection of higher nAb titres in the RVP assay compared to other assay formats similar to PRNT has previously been reported 12 . In addition, we noted that the ratio of RVP to PRNT titres was not fixed and varied with the animal model and viral isolate.
Immunogenicity of the nucleoside-modified ZIKV prM-E mRNA-LNP vaccine was next evaluated in BALB/c mice. E-protein-specific IgG in the serum peaked at week 8 and remained stable between weeks 8 and 20 (endpoint titres around 200,000; 90-130 μ g ml −1 ) ( Fig. 1e and Extended Data Fig. 3b ). PRNT 50 nAb increased to a maximum of about 1,100 at week 16 and remained stable until week 20 (Fig. 1f ). The RVP nAb titre rose to 50,000 at week 8 and remained above 20,000 until week 20 ( Fig. 1g) .
A challenge study was conducted in BALB/c mice immunized by intradermal injection of 30 μ g of nucleoside-modified ZIKV prM-E mRNA-LNP or poly(C) RNA-LNP. Mice were challenged by intravenous injection at week 2 (short term) or week 20 (long term) after immunization with 200 plaque-forming units (PFU) of ZIKV PRVABC59. In the short-term protection study, 8 out of 9 control mice showed the presence of viral RNA in the blood (viraemia) by day 3, with a median peak of around 14,000 copies per ml. All ZIKV mRNA-immunized mice (n = 9) were protected against detectable viraemia ( Fig. 2a ). In the long-term study, all control mice (n = 5) showed viraemia on day 3, with a median peak of 1,200 copies per LETTER RESEARCH ml, whereas none of the ZIKV mRNA-immunized mice (n = 10) had detectable viraemia at days 3 or 7 (Fig. 2b ). These data demonstrate that a single immunization with nucleoside-modified ZIKV prM-E mRNA-LNP rapidly elicits durable protection against detectable viraemia with a heterologous ZIKV strain in mice.
We next evaluated the efficacy of the nucleoside-modified ZIKV mRNA-LNP vaccine in rhesus macaques (Macaca mulatta), a nonhuman primate species that shows several features of ZIKV infection in humans 22 . Macaques were immunized by intradermal injection with doses of 600 μ g, 200 μ g or 50 μ g of nucleoside-modified ZIKV prM-E mRNA-LNP. Similar to mice, no inflammation or other adverse events were observed. E-protein-specific IgG and nAb were efficiently induced by all three vaccine doses, with no statistically significant differences between groups. Endpoint IgG titres rose to > 300,000 in all groups at week 4 and were maintained at ≥ 100,000 until week 12 (Fig. 3a) . PRNT 50 nAb titres against MR-766 peaked at about 400 at week 2 (Extended Data Fig. 4a ). To facilitate comparison of nAb titres across laboratories, the neutralization curve is shown for a human ZIKV-neutralizing monoclonal antibody, A3594, in the PRNT assay (Extended Data Fig. 5 ). nAb titres obtained with a focus-reduction neutralization test (FRNT), which has a format similar to PRNT, were stable around 400 against ZIKV MEX I-44 at weeks 2-12 (Fig. 3b ). The RVP assay showed nAb titres against H/PF/2013 of around 10,000 at week 2 and around 17,000 at week 4 (Fig. 3c) , and a titre of around 3,000 against MR-766 at week 4 (Extended Data Fig. 4b ). The neutralization of viruses from both Asian and African lineages is consistent with a previous report demonstrating the existence of only one serotype of ZIKV 23 . The absence of a significant dose-dependent effect in the antibody response in any assay (Kruskal-Wallis test, P > 0.05) suggests that a low dose of 50 μ g (approximately 0.02 mg kg −1 ) was sufficient, or possibly more than sufficient, to induce robust anti-ZIKV immunity in macaques.
Rhesus macaques were challenged at week 5 by subcutaneous injection of 10 4 TCID 50 of ZIKV PRVABC59 in five vaccinated animals and six control animals (Extended Data Table 1 ). All control animals became infected, with median peak plasma viraemia of 7,000 ZIKV RNA copies per ml (Fig. 4) . By contrast, vaccinated macaques were highly protected against ZIKV infection. Four out of five animalsincluding three that received the lowest dose of 50 μ g and one that received the medium dose of 200 μ g-had no detectable viraemia (< 50 copies per ml) at all time points. We detected a low and transient viral blip of 100 copies per ml at day 3 after challenge in one animal that received the highest dose of 600 μ g of ZIKV prM-E mRNA-LNP, representing a 99% reduction in peak viraemia compared to the control animals. This animal exhibited among the lowest nAb titres in multiple assays at week 4 after vaccination: PRNT 50 of 36 to MR-766, FRNT 50 of 226 to MEX I-44 and RVP titres of 986 to MR-766 and 5,812 to H/PF/2013 ( Fig. 3 and Extended Data Fig. 4) . The significance of a lowlevel viral blip in one animal, including implications for a correlate of protection, are as yet uncertain and warrant further study with a greater number of animals.
In this report, we demonstrate that a single, low-dose intradermal immunization with nucleoside-modified ZIKV prM-E mRNA-LNP is protective in both mice and rhesus macaques and elicits higher nAb responses than a single immunization of multiple ZIKV vaccine candidates that have recently been reported, including purified inactivated virus (PIV) and plasmid DNA vaccines encoding prM-E or M-E 10-12 . In mice, PRNT 50 nAb increased steadily over several months, rising to levels 50-100 times higher than those induced by a single immunization with PIV or DNA vaccines 11, 12 . The ZIKV mRNA-LNP vaccine conferred complete, rapid and durable protection in mice that was maintained for at least 5 months, and probably much longer, since nAb titres were stable. The challenge studies in mice also showed that ZIKV PRVABC59 replicated more efficiently (P = 0.02, Mann-Whitney test) in 8-week-old BALB/c mice compared to 25-week-old mice, when two identical aliquots and doses of challenge virus stock were used. A previous report has shown 
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that ZIKV-related mortality in immune-competent mice decreases between 1 and 4 weeks of age 24 , but ZIKV replication in adult mice has not yet been well described.
In rhesus macaques, a single immunization with 50 μ g ZIKV prM-E mRNA-LNP induced RVP nAb titres that were 50 times higher than those induced by one immunization with 1 mg DNA vaccine and over two times higher than those induced by two immunizations of DNA 12 , as measured by the same assay in the same laboratory. ZIKV mRNA-LNP nAb titres may overlap with those elicited by one injection of PIV or RhAd52 ZIKV vaccines in macaques, although differences in assay formats prevent a precise comparison. The FRNT nAb titres elicited by ZIKV mRNA-LNP in macaques were maintained at a stable level until 12 weeks after immunization, suggesting that protection may be durable.
Future studies on the nucleoside-modified ZIKV mRNA-LNP vaccine will allow us to explore the effect of a boost, study the effect of this vaccine on other flavivirus infections and determine the efficacy in preventing fetal ZIKV infection and disease. by secondary goat anti-mouse IgG HRP 1:10,000 for 1 h. Antibody incubations were performed at room temperature in blocking buffer. Blots were developed using Luminata Forte substrate (Millipore) and a Kodak X-OMAT 1000A processor. At least 2 independent experiments were performed. Characterization of E protein in supernatant. Supernatant from HEK293T cells transfected with ZIKV prM-E mRNA was tested for whether E protein could be pelleted and disrupted with detergent, consistent with subviral particles. Supernatant was incubated in PBS alone or PBS with 0.5% Triton X-100 for 1 h on ice. Samples were then spun at 42,000 r.p.m. for 2.5 h in a Beckman TLA-55 rotor. The supernatant was then removed from the pellet, which was resuspended in 50 μ l of PBS. Equal volumes of the input, pellet and post-centrifugation supernatant fractions were then analysed by western blot, as described above. Lipid-nanoparticle encapsulation of the mRNA. FPLC-purified mRNA and polycytidylic acid (poly(C) RNA) (Sigma) were encapsulated in LNPs using a self-assembly process in which an aqueous solution of mRNA at pH 4.0 is rapidly mixed with a solution of lipids dissolved in ethanol 29 . LNPs used in this study were similar in composition to those described previously 29, 30 , which contain an ionizable cationic lipid (proprietary to Acuitas), phosphatidylcholine, cholesterol and PEG-lipid (with a ratio of 50:10:38.5:1.5 mol/mol) and were encapsulated at an RNA to total lipid ratio of around 0.05 (wt/wt). The LNPs had a diameter of around 80 nm as measured by dynamic light scattering using a Zetasizer Nano ZS instrument (Malvern Instruments Ltd). RNA-LNP formulations were stored at − 80 °C at a concentration of RNA of about 1 μ g μ l −1 . Administration of LNPs to mice and rhesus monkeys. Mice. Female BALB/c and C57BL/6 mice aged 8 weeks were purchased from Charles River Laboratories, and cages of mice were randomly allocated to groups. Power analysis was used to calculate the size of all animal groups to ensure statistically significant results. RNA-LNP was diluted in PBS and injected into animals intradermally with a 3/10cc 29½G insulin syringe (BD Biosciences). Four sites of injection (30 μ l each) over the lower back were used. Monkeys. Ketamine-anaesthetized animals were shaved on their back and injected with mRNA-LNP diluted in PBS. Ten sites of injection (60 μ l each) were used. Animals of similar age and weight were allocated to each group. Blood collection from mice and rhesus macaques. Mice. Blood was collected from the orbital sinus under isoflurane anaesthesia. Blood was centrifuged for 10 min at 13,000 r.p.m. and the serum was stored at − 20 °C and used for ELISA and virus neutralization assays. EDTA-plasma was collected to isolate RNA for quantitative PCR with reverse transcription (qRT-PCR) analysis.
Monkeys. Blood was collected by femoral venipuncture under ketamine anaesthesia, and serum and EDTA-plasma were collected and stored at − 80 °C for ELISA, neutralization analysis and to isolate RNA for qRT-PCR. Stimulation and staining of splenocytes. Single-cell suspensions from spleens were made in complete medium. Splenocytes were washed once in PBS and resuspended in complete medium at 2 × 10 7 cells per ml. Subsequently, 2 × 10 6 cells (100 μ l) per sample were stimulated for 6 h at 37 °C using 2 μ g ml −1 purified, recombinant ZIKV E protein. GolgiPlug (brefeldin A, BD Biosciences) and GolgiStop (monensin, BD Biosciences) were diluted 1:100 and 1:143 in complete medium, respectively, and 20 μ l from both diluted reagents was added to each sample to inhibit the secretion of intracellular cytokines after 1 h. An unstimulated sample for each animal was included. Samples stimulated with PMA (10 ng ml −1 )-ionomycin (250 ng ml −1 ) (Sigma) were used as positive controls.
After stimulation, cells were washed in PBS and stained using the live/dead fixable aqua dead cell stain kit (Life Technologies) and then surface stained for CD4 and CD27. Antibodies were incubated with cells for 30 min at room temperature. Following surface staining, cells were washed in FACS buffer and fixed using the Cytofix/Cytoperm kit (BD Biosciences) according to the manufacturer's instructions. Following fixation, the cells were washed in the appropriate perm buffer and incubated with antibodies against CD3, TNF, IFNγ and IL-2 for 1 h at room temperature. Following staining, the cells were washed with the appropriate perm buffer, fixed (PBS containing 1% paraformaldehyde) and stored at 4 °C until analysis. Results are obtained from one technical replicate. Flow cytometry. Splenocytes were analysed on a modified LSR II flow cytometer (BD Biosciences). One hundred thousand events were collected per sample. After the gates for each function were created, the Boolean gate platform was used to create the full array of possible combination of cytokines, equating to seven response patterns when testing three cytokines. Data were expressed by subtracting the per cent positive unstimulated cells from the per cent positive cells stimulated with E protein.
Enzyme-linked immunosorbent assays (ELISA) for ZIKV E-specific IgG.
Immulon 4HXB ELISA plates were coated with 6 μ g ml −1 purified, recombinant ZIKV E protein in 0.1 M sodium bicarbonate buffer overnight at 4 °C. The plate was blocked with 2% BSA in PBS for 1 h, and washed three times with wash buffer (PBS
